Stroke-related parameters affecting the deterioration of oral health-related quality of life as measured by OHIP-14 three months after ischemic stroke Authors: Joanna Slowik, Pawel Wrona, Tomasz Homa, Bartosz Kolodziejczyk, Maciej Dzierzak, Malgorzata Dec-Cwiek, Marcin Wnuk Published: 2025 ABSTRACT ObjectivesOral health-related quality of life (OHRQoL) depends not only on oral diseases and hygiene but also on various psychosocial and medical conditions, including stroke and its complications. This study aimed to identify parameters influencing deterioration of OHRQoL, measured with the Oral Health Impact Profile-14 (OHIP-14) questionnaire from the acute stroke onset to 3 months later.MethodsWe prospectively analyzed data from 392 participants in the iBioStroke project, all of whom completed OHIP-14 questionnaire during the acute phase of ischemic stroke and again 3 months after its onset. We considered 37 demographic, clinical, radiological, and biochemical parameters available during the acute phase of stroke, as well as cognitive and mood disturbances that occurred during the follow-up period between two groups: Group I, consisting of patients whose OHIP-14 scores remained stable or decreased (OHRQoL stable or improved) by at least 1 point between the acute phase of stroke and 3 months after its onset, and Group II, comprising those whose OHIP-14 scores increased (OHRQoL deteriorated) by at least 1 point in the total score over the same period of time.ResultsUnivariate regression testing revealed that patients in Group II (n = 189), compared to Group I (n = 203), more frequently presented with consistent anxiety (OR = 2.67, 95%CI: 1.49–4.87, p = 0.001) and consistent depression (OR = 2.10, 95%CI: 1.07–4.23, p = 0.033). Additionally, they were more likely to experience deterioration of pre-existing anxiety (OR = 2.88, 95%CI: 1.64–5.14, p < 0.001) and depression (OR = 2.42, 95%CI: 1.45–4.11, p < 0.001). Patients who experienced deterioration in their OHRQoL exhibited higher platelet count (mean values: 235.5 ± 78.7 vs. 218.2 ± 62.8 × 103/uL, OR = 1.00, 95%CI: 1.00–1.01, p = 0.019) compared to those who did not. Logistic regression analysis indicated that deterioration of anxiety (OR = 2.20, 95%CI: 1.20–4.09, p = 0.011), consistent anxiety (OR = 2.16, 95%CI: 1.15–4.11, p = 0.018), and higher platelet count (OR = 1.00, 95%CI: 1.00–1.01, p = 0.05) were independent risk factors for deterioration of OHRQoL as measured with the OHIP-14 questionnaire between the acute phase of stroke and 3 months after its onset.ConclusionsOur study reveals that over 48% of ischemic stroke patients experience a decline in their OHRQoL. Our findings also highlight the necessity for vigilant monitoring of post-stroke anxiety both during the acute phase of stroke and throughout follow-up, as it impacts the risk of deterioration in OHRQoL. This issue holds significance because post-stroke anxiety is treatable with psychological and pharmacological interventions.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12903-025-07264-9. Introduction Stroke is a leading cause of disability, morbidity, and mortality worldwide, with its global burden continuously increasing [1]. According to the newest report of the National Health Fund (NFZ), the only state payer covering the whole population of Poland, the incidence of ischemic stroke increased from 134.4 in 2000 to 145.9 per 100 000 inhabitants in 2019 [2]. Moreover, in 2021, ischemic stroke accounted for 4.2% of the total Disability-Adjusted Life Years (DALYs) due to all diseases in Poland, whereas mortality rate 90 days after hospital admission was 23% [2]. The consequences of stroke extend beyond physical disability to include communication problems, swallowing difficulties, mood disorders – such as post-stroke depression (PSD) and post-stroke anxiety (PSA) – and cognitive impairments. These factors can significantly affect post-stroke quality of life [3]. Quality of life is a multidimensional concept encompassing the physical, psychological, social, and daily living activities from an individual’s perspective [4]. Oral health-related quality of life (OHRQoL), a specific subtype of quality of life, assesses how oral diseases, oral hygiene, and various psychosocial or medical conditions impact individuals’ perceptions of their oral health, affecting all aspects of their daily activities [5]. Previous studies also indicated the association between oral health and stroke. For example, a recent analysis of UK Biobank data confirmed that during 14 years of observation people with periodontal disease exhibited an increased risk of ischemic stroke [6]. Furthermore, as shown in patient cohorts from Korea and Taiwan, gingivitis or tooth loss increased the risk of stroke among individuals aged 50 or more [7], whereas severe dental caries posed a significantly higher risk of stroke [8]. However, its etiology depended on age, with ischemic and hemorrhagic stroke positively associated with ≥ 40 and < 40 years, respectively [8]. Previous studies have identified a range of factors associated with worsened OHRQoL post-stroke. These factors include: (1) objective indicators of current oral health status, such as an increased number of carious teeth, fewer remaining teeth, poorer prosthetic status, and worse periodontal condition [9, 10]; (2) poorer health behaviors related to oral hygiene, including the absence of a regular tooth brushing habit during hospitalization [11], low frequency of dental visits [10, 12], short duration of tooth brushing sessions, and infrequent toothbrush replacement [13]; and (3) socio-demographic factors, such as older age, male sex, and shorter duration of education [13]. Additionally, neurological deficits related to stroke, such as increased severity of neurological impairment [13], reduced upper extremity function [14], speech or cognitive deficits, and swallowing problems, have been associated with decreased OHRQoL [15, 16]. Patients after ischemic stroke in Poland might also face other difficulties possibly influencing OHRQoL, such as the access to immediate post-stroke rehabilitation that varies across the country [2], or availability of dental services, that might not be fully covered by the NFZ and could be difficult to access due to economic constraints or physical disability [10]. A recent systematic review on OHRQoL in patients after stroke included only 8 studies and most of them had a cross-sectional design [17]. Furthermore, among studies evaluating OHRQoL twice after stroke, cohorts of patients were small and only two of them were investigated with the use of OHIP-14 questionnaire for comparisons [11, 12]. So far, in Poland only two studies assessed OHRQoL, i.e. in patients after ischemic stroke in north-west area of the country (Szczecin) [10] and among older residents of Wroclaw (south-west region of Poland) [18]; however, both studies had a cross-sectional design. Therefore, due to methodological and sample restrictions in the previous research, the aim of the current study was to investigate the parameters influencing the deterioration of OHRQoL, as assessed with the OHIP-14 questionnaire, between the acute phase of stroke and 3 months after its onset. Our analysis considered demographic, clinical, radiological, and biochemical factors collected during the acute stroke phase. Additionally, we accounted for cognitive and mood disturbances that emerged during the follow-up period. Methods Study participants We enrolled acute ischemic stroke (AIS) patients admitted to the Comprehensive Stroke Center at the University Hospital in Krakow, Poland, between July 18, 2020, and December 14, 2022. Demographic, clinical, radiological, and laboratory data were prospectively collected following the protocol of the study ‘Identification and Clinical Validation of Biomarkers for Long-Term Outcome After Cerebral Ischemia (iBioStroke)’, as detailed elsewhere [19]. The inclusion criteria for the iBioStroke study were as follows: first-ever ischemic stroke, age of 18 years or older, and signed consent to participate. The exclusion criteria included: a modified Rankin Scale (mRS) score greater than 2 before stroke, a diagnosis of dementia and depression before stroke, based on information from patient, family member/caregiver, and/or clinical documentation (if available), the presence of a concomitant chronic neurodegenerative disorder (i.e., Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, etc.), a concurrent chronic autoimmune disorder, regardless of the affected organ, and cancer. When assessing cognition before stroke, each patient, family member or caregiver were interviewed with a few structured questions, that were about: remembering things about family and friends, remembering things that happened recently, remembering patients’ address and telephone number, day, month, year, remembering where things were usually kept, knowing how to use household appliances, learning new things, making decision on everyday matters, handling the money for shopping and all financial matters, and making logical decisions in everyday challenges. Only patients without any dysfunction regarding the abovementioned questions were invited to participate in the current study [19]. Standardized stroke care was provided according to the Polish guidelines for stroke care [20], that were in line with the European Stroke Organisation guidelines for stroke care (https://eso-stroke.org/guidelines/eso‐guideline‐directory). All procedures complied with the Declaration of Helsinki [21]. All patients signed informed consent to participate in the current study. The Jagiellonian University Ethical Committee approved the study protocol (1072.6120.118.2020). Analyzed clinical parameters and laboratory data In the current study, we analyzed demographics, including age, sex, and years of education, as well as the stroke risk factor profile [22]. We also analyzed the set of standardized clinical, radiological and biochemical parameters that were routinely measured in acute stroke according to the commonly recommended guidelines [20] (https://eso-stroke.org/guidelines/eso‐guideline‐directory). Platelet count was one of such parameters; the rationale for its choice was also the fact that platelet count was previously linked to systemic inflammation [23] and oral health outcomes [24]. Furthermore, we assessed neurological deficit using the National Institutes of Health Stroke scale (NIHSS) twice, i.e. upon admission and 24 h after stroke onset [25]. Delta NIHSS was defined as the difference between the NIHSS score at 24 h post-stroke and the score recorded at hospital admission. We evaluated the degree of disability using the modified Rankin Scale (mRS) before stroke, at hospital discharge and again 3 months after stroke onset. The mRS was dichotomized into good (0–2 points) and poor outcomes (3–6 points) [26]. Upon admission, body temperature and systolic and diastolic blood pressure were measured. Patients also underwent a standardized neuroimaging study protocol as previously described [19]. Details regarding imaging parameters assessed in the current study can be found in the Appendix. Medical complications were diagnosed as previously described [27]. Stroke etiology – comprising small vessel disease stroke, large vessel disease stroke, cardioembolic stroke, stroke of rare etiology, and stroke of unknown origin – was classified according to the TOAST criteria (Trial of ORG 10172 in Acute Stroke Treatment) [28]. The causal treatment consisted of intravenous thrombolysis with alteplase (IVT), mechanical thrombectomy (MT), or a combination of both [29]. On day 1, we analyzed the following fasting blood tests: C-reactive protein (CRP), white blood cell count (WBC), platelet count (PLT), fibrinogen levels, International Normalized Ratio (INR), creatinine, hemoglobin, glucose, total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride levels. Assessment with clinical scales – MoCA, HADS and OHIP-14 Cognitive decline was evaluated both at discharge from the hospital and 3 months later during a follow-up visit, utilizing the Montreal Cognitive Assessment (MoCA) test [30]. Depression and anxiety were also measured twice, i.e. at discharge and 3 months after stroke onset, using the Hospital Anxiety and Depression Scale (HADS) questionnaire. Details regarding these tests and their scoring cutoffs used in the current study can be found in the Appendix. During hospitalization and 90 days post-stroke onset, researchers administered the Oral Health Impact Profile-14 (OHIP-14) questionnaire to measure OHRQoL that was previously published elsewhere [31]. The OHIP-14 is a self-administered tool designed to assess the impact of oral conditions resulting from oral diseases on an individual’s quality of life [31]. In this study, the validated Polish version of OHIP-14 was given to stroke patients [32]. The questionnaire evaluates oral health issues faced within the past 4 weeks and encompasses seven domains, each containing two questions, or subdomains: functional limitation (Q1: difficulty pronouncing words, Q2: worsened taste), physical pain (Q3: painful aching, Q4: uncomfortable eating), psychological discomfort (Q5: self-consciousness, Q6: feeling tense), physical disability (Q7: unsatisfactory diet, Q8: interrupted meals), psychological disability (Q9: difficulty relaxing, Q10: embarrassment), social disability (Q11: irritability with others, Q12: difficulty performing jobs), and social handicap (Q13: unsatisfying life, Q14: inability to function). Each question is rated on a 5-point Likert scale: 0 (never experienced), 1 (sometimes experienced), 2 (definitely experienced), 3 (often experienced), and 4 (very frequently experienced). The total score, which is the sum of scores for each domain, ranges from 0 to 56. A higher score indicates a worse OHRQoL. The OHIP-14 questionnaire was chosen to measure OHRQoL among participants of the current study, as it was the most commonly used and reliable tool for this purpose [33], especially helpful in identifying concomitant psychological problems [12]. In the present study, we compared the parameters between two groups of patients. Group I consisted of patients whose OHIP-14 scores remained stable or decreased (OHRQoL stable or improved) by at least 1 point between acute stroke phase and 3 months after its onset, whereas Group II comprised those whose OHIP-14 scores increased (OHRQoL deteriorated) by at least 1 point over the same period of time. We used the period of 3 months post-stroke onset to assess OHIP-14 for the second time as previous studies showed that functional outcome at this timeline predicted long-term survival [34] and was perceived as a golden period of post-stroke recovery [35]. The OHIP-14 questionnaire was administered as early as possible during hospitalization but not later than on the day 8. after stroke onset. Two hundred ninety three (55%) patients performed OHIP-14 questionnaire within 48 h after stroke. The group of patients who performed OHIP-14 questionnaire later, made this due to acute stroke-related temporal complications, i.e. cognitive problems, mood disorders, neurological and medical complications. The questionnaire was administered when a researcher was sure that the patient was able to understand and communicate. However, to eliminate limitations related to the dysfunction of the paretic upper limb, in 34% of patients an interviewer-administered approach was used. Three months after stroke onset the OHIP-14 questionnaire was administered in the outpatient clinic for stroke patients, and the questionnaire was administered in interview form only in 11 participants. Statistical analysis The study had 80% power to detect a 1-point change in the OHIP-14 score between the acute phase of ischemic stroke and 3 months after its onset at the 0.05 significance level. To demonstrate such a difference or greater, a minimum of 313 subjects were required, based on values from a published article [36]. Descriptive statistics were presented as frequencies and percentages for categorical variables and as means and standard deviations or as medians with interquartile ranges for numerical variables, depending on their distribution normality. To compare variables between the groups mentioned, Pearson’s Chi-squared tests and Fisher’s exact tests were employed for categorical variables, while Wilcoxon rank sum tests were used for numerical variables. Logistic regression analysis was conducted to compare the outcome groups. Results from both univariate and multivariable logistic regression were presented. In the multivariable models, we included variables that demonstrated significant associations with OHIP-14 improvement or deterioration in univariate analyses (p < 0.05) and showed no substantial collinearity with other independent variables (correlation coefficient r < 0.5). The final age- and sex-adjusted model included the HADS-A anxiety subscale and platelet count as the predictors. The multivariable logistic regression model was chosen using a stepwise selection method with a backward elimination algorithm, with the significance level set at 0.05. Results were expressed as odds ratios (OR), 95% confidence intervals (CI) for the OR, and corresponding p-values. All calculations were performed using R statistical software, version 4.2.1 (Copyright © 2022 The R Foundation for Statistical Computing). Data availability The datasets used and analyzed during the current study are available from the corresponding author on reasonable request. Results During the study period, our center admitted 1,809 patients diagnosed with AIS. Of these, 1,042 patients met the inclusion and exclusion criteria for the iBioStroke study. Additionally, 416 patients completed the OHIP-14 questionnaire twice, once during hospitalization and again 3 months after stroke onset. The final analysis included 392 patients who had complete data on cognition assessed with the use of MoCA test, and mood evaluated with HADS questionnaire. These assessments were conducted at discharge and 3 months later. A flowchart showing detailed recruitment process for the current study was provided in Fig. 1. Fig. 1A flowchart showing recruitment of participants for the current study (HADS – Hospital Anxiety and Depression Scale, MoCA – Montreal Cognitive Assessment, OHIP-14 – Oral Health Impact Profile-14) A flowchart showing recruitment of participants for the current study (HADS – Hospital Anxiety and Depression Scale, MoCA – Montreal Cognitive Assessment, OHIP-14 – Oral Health Impact Profile-14) One hundred two patients (26.0%) maintained steady OHIP-14 scores from the time of acute stroke to 3 months later. An improvement in OHRQoL as measured with the OHIP-14 questionnaire during this period was observed in 101 patients (25.8%), with a median change of 4 points (interquartile range [IQR]: 2–10). Conversely, a deterioration in OHRQoL as measured with the OHIP-14 questionnaire was noted in 189 patients (48.2%), with a median decline of 6 points (IQR: 2–13). Table 1 presents the demographic, clinical, radiological, and biochemical characteristics of two groups: Group I, which includes patients who showed either steady results or improvement in their OHRQoL between the acute stroke and 3 months later, and Group II, which consists of patients whose OHRQoL deteriorated during the same period. Our group of participants consisted of 392 individuals, with a mean age of 66.1 years; 44.1% of them were women. Among patients who deteriorated in OHRQoL in comparison to those with steady state or improvement, we observed a trend towards older age (67.4 vs. 64.9 years, p = 0.11) and lower number of years of education (12.0 vs. 12.6 years, p = 0.11; see Table 1). Most of the subjects suffered from hypertension, 1 out of 5 had diabetes mellitus and 1 out of 4 were smokers. No significant differences were found in the prevalence of stroke risk factors between Group I and II. Causative treatment in the acute phase of stroke, i.e. IVT and/or MT, was administered in 66.1% of patients. Individuals in Group I and II did not differ in terms of biochemical parameters, including cholesterol levels, however, those who deteriorated in OHRQoL compared to remainders exhibited significantly higher platelet count (235.5 vs. 218.2 × 103/ul, p = 0.023). Table 1Baseline characteristics of the studied population, comparison between two outcome groups (odds ratios with 95% confidence intervals) of univariate logistic regression models for the probability of group I (steady-state or improvement in OHRQoL as measured with the OHIP-14) vs. group II (deterioration in OHRQoL in the OHIP-14) three months after strokeCharacteristicsAll patients [A],N = 3921Group I: steady state or improvement in OHIP-14 [B],N = 2031Group II: deterioration in OHIP-14 [C],N = 1891p-value2[B vs. C]OR (95%CI)[univariate logistic regression]p-value3[univariate logistic regression]DemographicsFemale sex (n, %)173 (44.1%)86 (42.4%)87 (46.0%)0.51.16 (0.78, 1.73)0.465Age [years] (mean ± SD)66.1 ± 13.264.9 ± 13.367.4 ± 13.10.111.01 (1.00, 1.03)0.061Years of education (mean ± SD)12.3 ± 2.912.6 ± 3.012.0 ± 2.90.110.94 (0.87, 1.00)0.058Stroke risk factorsHypertension (n, %)285 (72.7%)147 (72.4%)138 (73.0%)0.91.03 (0.66, 1.61)0.894Diabetes mellitus (n, %)79 (20.2%)36 (17.7%)43 (22.8%)0.21.37 (0.83, 2.25)0.217Ischemic heart disease (n, %)113 (28.8%)57 (28.1%)56 (29.6%)0.71.08 (0.70, 1.67)0.735Atrial fibrillation (n, %)93 (23.7%)47 (23.2%)46 (24.3%)0.81.07 (0.67, 1.70)0.783Previous stroke (n, %)54 (14.1%)31 (15.7%)23 (12.4%)0.40.76 (0.42, 1.35)0.355Smoking (n, %)101 (25.8%)50 (24.6%)51 (27.0%)0.61.13 (0.72, 1.78)0.595Clinical parametersmRS before stroke > 0 (n, %)56 (14.3%)23 (11.3%)33 (17.5%)0.0831.66 (0.94, 2.97)0.085delta NIHSS (mean ± SD)4.0 ± 5.74.1 ± 5.63.9 ± 5.90.70.99 (0.96, 1.03)0.722Initial body temperature [C] (mean ± SD)36.5 ± 0.336.5 ± 0.336.5 ± 0.30.60.74 (0.36, 1.50)0.4Initial systolic blood pressure [mmHg] (mean ± SD)150.9 ± 25.9150.2 ± 23.7151.6 ± 28.2> 0.91 (0.99, 1.01)0.596Initial diastolic blood pressure [mmHg] (mean ± SD)85.8 ± 15.985.5 ± 16.186.0 ± 15.70.91 (0.99, 1.01)0.75Radiological parametersStroke volume on admission [ml] (mean ± SD)8.5 ± 19.76.7 ± 15.010.2 ± 23.40.41.01 (1.00, 1.02)0.126Penumbra volume on admission [ml] (mean ± SD)48.4 ± 58.046.2 ± 60.350.6 ± 55.70.41 (1.00, 1.01)0.507Hemorrhagic transformation on CT 24 h after admission (n, %)47 (12.0%)24 (11.8%)23 (12.2%)> 0.91.03 (0.56, 1.91)0.916Stroke topography left hemisphere vs. other (n, %)0.9 right hemisphere/cerebellum/brainstem246 (62.9%)127 (62.6%)119 (63.3%)-- left hemisphere145 (37.1%)76 (37.4%)69 (36.7%)0.97 (0.64, 1.46)0.88Global cortical atrophy (mean ± SD)10.7 ± 6.110.4 ± 6.210.9 ± 6.10.31.01 (0.98, 1.05)0.439 Stroke etiology Unknown etiology (n, %)187 (47.7%)95 (46.8%)92 (48.7%)0.2-- Large vessel disease (n, %)61 (15.6%)26 (12.8%)35 (18.5%)1.39 (0.78, 2.51)0.268 Cardioembolic stroke (n, %)109 (27.8%)59 (29.1%)50 (26.5%)0.88 (0.54, 1.40)0.581 Small vessel disease (n, %)15 (3.8%)8 (3.9%)7 (3.7%)0.9 (0.31, 2.62)0.85 Rare etiology (n, %)20 (5.1%)15 (7.4%)5 (2.6%)0.34 (0.11, 0.93)0.047 *TreatmentCausative treatment (IVT, MT or IVT + MT) (n, %)259 (66.1%)136 (67.0%)123 (65.1%)0.70.92 (0.60, 1.40)0.689IVT (n, %)194 (49.5%)101 (49.8%)93 (49.2%)> 0.90.98 (0.66, 1.45)0.914MT (n, %)162 (41.3%)83 (40.9%)79 (41.8%)0.91.04 (0.69, 1.55)0.855IVT + MT (n, %)97 (24.7%)48 (23.6%)49 (25.9%)0.61.13 (0.71, 1.79)0.601Stroke associated infections that require antibiotic treatment during hospitalization (n, %)67 (17.1%)28 (13.8%)39 (20.6%)0.0721.62 (0.96, 2.79)0.074Biochemical parametersWBC count [uL] (mean ± SD)8.6 ± 3.08.7 ± 3.18.4 ± 3.00.30.97 (0.91, 1.04)0.436PLT count [x 103 /uL] (mean ± SD)226.6 ± 71.4218.2 ± 62.8235.5 ± 78.70.023 *1 (1.00, 1.01)0.019 *INR (mean ± SD)1.1 ± 0.61.1 ± 0.81.0 ± 0.40.50.92 (0.56, 1.29)0.65CRP [mg/L] (mean ± SD)8.8 ± 17.78.6 ± 17.49.0 ± 18.0> 0.91 (0.99, 1.01)0.832Fibrinogen [g/L] (mean ± SD)2.8 ± 2.22.7 ± 0.83.0 ± 3.10.71.1 (0.97, 1.37)0.324Creatinine levels[umol/L] (mean ± SD)85.0 ± 47.086.8 ± 59.683.0 ± 27.70.41 (0.99, 1.00)0.444Hemoglobin levels [g/dl] (mean ± SD)13.6 ± 1.713.7 ± 1.813.5 ± 1.70.20.93 (0.83, 1.05)0.234Glucose levels [ mg/dl](mean ± SD)120.8 ± 49.1119.6 ± 52.1122.0 ± 45.60.31 (1.00, 1.01)0.633Total cholesterol levels [mmol/L] (mean ± SD)4.6 ± 1.24.6 ± 1.24.5 ± 1.20.20.89 (0.75, 1.05)0.158Total LDL levels [mmol/L] (mean ± SD)2.6 ± 1.12.7 ± 1.02.6 ± 1.10.30.91 (0.75, 1.10)0.323Total HDL levels [mmol/L] (mean ± SD)1.3 ± 0.41.3 ± 0.41.3 ± 0.40.60.79 (0.45, 1.37)0.41Total triglycerides levels [mmol/L] (mean ± SD)1.4 ± 0.91.5 ± 1.21.4 ± 0.60.80.86 (0.66, 1.07)0.21Cognitive impairment based on MoCA test at baseline and after 90 days (n, %)Consistently normal cognition: No cognitive impairment on baseline (MoCA: 23–30) and no cognitive impairment three months after stroke (MoCA: 23–30)150 (40.2%)84 (43.3%)66 (36.9%)0.3--Deterioration of cognitive performance: No cognitive impairment on baseline (MoCA: 23–30) and cognitive impairment three months after stroke (MoCA: 0–22)37 (9.9%)21 (10.8%)16 (8.9%)0.97 (0.46, 2.00)0.934Consistent cognitive decline: Cognitive impairment on baseline (MoCA: 0–22) and cognitive impairment three months after stroke (MoCA: 0–22)131 (35.1%)59 (30.4%)72 (40.2%)1.55 (0.97, 2.50)0.067Improvement of cognitive performance: Cognitive impairment on baseline (MoCA: 0–22) and no cognitive impairment three months after stroke (MoCA: 23–30)55 (14.7%)30 (15.5%)25 (14.0%)1.06 (0.57, 1.97)0.853Anxiety based on HADS- A - anxiety subscale at baseline and after 90. Days (n, %)Consistently no anxiety: No anxiety at baseline (HADS-A: 0–7); no anxiety after 3 months (HADS-A: 0–7)169 (45.4%)103 (54.2%)66 (36.3%)< 0.001 *--Deterioration in anxiety: no anxiety at baseline (HADS-A: 0–7); anxiety after 3 months (HADS-A: >7)74 (19.9%)26 (13.7%)48 (26.4%)2.88 (1.64, 5.14)< 0.001 *Consistent anxiety: anxiety at baseline (HADS-A: >7); anxiety after 3 months (HADS-A: >7)65 (17.5%)24 (12.6%)41 (22.5%)2.67 (1.49, 4.87)0.001 *Improvement in anxiety: anxiety at baseline (HADS-A: >7); no anxiety after 3 months (HADS-A: 0–7)64 (17.2%)37 (19.5%)27 (14.8%)1.14 (0.63, 2.04)0.663Depression based on HADS- D - depression subscale (at baseline and after 90 days (n, %)Consistently no depression: No depression at baseline (HADS-D: 0–7); no depression after 3 months (HADS-D: 0–7)218 (58.6%)125 (65.4%)93 (51.4%)< 0.001 *--Deterioration in depression: no depression at baseline (HADS-D: 0–7); depression after 3 months (HADS-D:>7)84 (22.6%)30 (15.7%)54 (29.8%)2.42 (1.45, 4.11)< 0.001 *Consistent depression: depression at baseline (HADS-D:>7); depression after 3 months (HADS-D:>7)41 (11.0%)16 (8.4%)25 (13.8%)2.10 (1.07, 4.23)0.033 *Improvement in depression: depression at baseline (HADS-D:>7); no depression after 3 months (HADS-D: 0–7)29 (7.8%)20 (10.5%)9 (5.0%)0.6 (0.25, 1.35)0.236 mRS score at hospital discharge 0–2 (n, %)338 (86.2%)181 (89.2%)157 (83.1%)0.08-- 3–5 (n, %)54 (13.8%)22 (10.8%)32 (16.9%)1.68 (0.94, 3.04)0.0821n (%)2Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test3Univariate logistic regression*statistically significant result Table 1Baseline characteristics of the studied population, comparison between two outcome groups (odds ratios with 95% confidence intervals) of univariate logistic regression models for the probability of group I (steady-state or improvement in OHRQoL as measured with the OHIP-14) vs. group II (deterioration in OHRQoL in the OHIP-14) three months after strokeCharacteristicsAll patients [A],N = 3921Group I: steady state or improvement in OHIP-14 [B],N = 2031Group II: deterioration in OHIP-14 [C],N = 1891p-value2[B vs. C]OR (95%CI)[univariate logistic regression]p-value3[univariate logistic regression]DemographicsFemale sex (n, %)173 (44.1%)86 (42.4%)87 (46.0%)0.51.16 (0.78, 1.73)0.465Age [years] (mean ± SD)66.1 ± 13.264.9 ± 13.367.4 ± 13.10.111.01 (1.00, 1.03)0.061Years of education (mean ± SD)12.3 ± 2.912.6 ± 3.012.0 ± 2.90.110.94 (0.87, 1.00)0.058Stroke risk factorsHypertension (n, %)285 (72.7%)147 (72.4%)138 (73.0%)0.91.03 (0.66, 1.61)0.894Diabetes mellitus (n, %)79 (20.2%)36 (17.7%)43 (22.8%)0.21.37 (0.83, 2.25)0.217Ischemic heart disease (n, %)113 (28.8%)57 (28.1%)56 (29.6%)0.71.08 (0.70, 1.67)0.735Atrial fibrillation (n, %)93 (23.7%)47 (23.2%)46 (24.3%)0.81.07 (0.67, 1.70)0.783Previous stroke (n, %)54 (14.1%)31 (15.7%)23 (12.4%)0.40.76 (0.42, 1.35)0.355Smoking (n, %)101 (25.8%)50 (24.6%)51 (27.0%)0.61.13 (0.72, 1.78)0.595Clinical parametersmRS before stroke > 0 (n, %)56 (14.3%)23 (11.3%)33 (17.5%)0.0831.66 (0.94, 2.97)0.085delta NIHSS (mean ± SD)4.0 ± 5.74.1 ± 5.63.9 ± 5.90.70.99 (0.96, 1.03)0.722Initial body temperature [C] (mean ± SD)36.5 ± 0.336.5 ± 0.336.5 ± 0.30.60.74 (0.36, 1.50)0.4Initial systolic blood pressure [mmHg] (mean ± SD)150.9 ± 25.9150.2 ± 23.7151.6 ± 28.2> 0.91 (0.99, 1.01)0.596Initial diastolic blood pressure [mmHg] (mean ± SD)85.8 ± 15.985.5 ± 16.186.0 ± 15.70.91 (0.99, 1.01)0.75Radiological parametersStroke volume on admission [ml] (mean ± SD)8.5 ± 19.76.7 ± 15.010.2 ± 23.40.41.01 (1.00, 1.02)0.126Penumbra volume on admission [ml] (mean ± SD)48.4 ± 58.046.2 ± 60.350.6 ± 55.70.41 (1.00, 1.01)0.507Hemorrhagic transformation on CT 24 h after admission (n, %)47 (12.0%)24 (11.8%)23 (12.2%)> 0.91.03 (0.56, 1.91)0.916Stroke topography left hemisphere vs. other (n, %)0.9 right hemisphere/cerebellum/brainstem246 (62.9%)127 (62.6%)119 (63.3%)-- left hemisphere145 (37.1%)76 (37.4%)69 (36.7%)0.97 (0.64, 1.46)0.88Global cortical atrophy (mean ± SD)10.7 ± 6.110.4 ± 6.210.9 ± 6.10.31.01 (0.98, 1.05)0.439 Stroke etiology Unknown etiology (n, %)187 (47.7%)95 (46.8%)92 (48.7%)0.2-- Large vessel disease (n, %)61 (15.6%)26 (12.8%)35 (18.5%)1.39 (0.78, 2.51)0.268 Cardioembolic stroke (n, %)109 (27.8%)59 (29.1%)50 (26.5%)0.88 (0.54, 1.40)0.581 Small vessel disease (n, %)15 (3.8%)8 (3.9%)7 (3.7%)0.9 (0.31, 2.62)0.85 Rare etiology (n, %)20 (5.1%)15 (7.4%)5 (2.6%)0.34 (0.11, 0.93)0.047 *TreatmentCausative treatment (IVT, MT or IVT + MT) (n, %)259 (66.1%)136 (67.0%)123 (65.1%)0.70.92 (0.60, 1.40)0.689IVT (n, %)194 (49.5%)101 (49.8%)93 (49.2%)> 0.90.98 (0.66, 1.45)0.914MT (n, %)162 (41.3%)83 (40.9%)79 (41.8%)0.91.04 (0.69, 1.55)0.855IVT + MT (n, %)97 (24.7%)48 (23.6%)49 (25.9%)0.61.13 (0.71, 1.79)0.601Stroke associated infections that require antibiotic treatment during hospitalization (n, %)67 (17.1%)28 (13.8%)39 (20.6%)0.0721.62 (0.96, 2.79)0.074Biochemical parametersWBC count [uL] (mean ± SD)8.6 ± 3.08.7 ± 3.18.4 ± 3.00.30.97 (0.91, 1.04)0.436PLT count [x 103 /uL] (mean ± SD)226.6 ± 71.4218.2 ± 62.8235.5 ± 78.70.023 *1 (1.00, 1.01)0.019 *INR (mean ± SD)1.1 ± 0.61.1 ± 0.81.0 ± 0.40.50.92 (0.56, 1.29)0.65CRP [mg/L] (mean ± SD)8.8 ± 17.78.6 ± 17.49.0 ± 18.0> 0.91 (0.99, 1.01)0.832Fibrinogen [g/L] (mean ± SD)2.8 ± 2.22.7 ± 0.83.0 ± 3.10.71.1 (0.97, 1.37)0.324Creatinine levels[umol/L] (mean ± SD)85.0 ± 47.086.8 ± 59.683.0 ± 27.70.41 (0.99, 1.00)0.444Hemoglobin levels [g/dl] (mean ± SD)13.6 ± 1.713.7 ± 1.813.5 ± 1.70.20.93 (0.83, 1.05)0.234Glucose levels [ mg/dl](mean ± SD)120.8 ± 49.1119.6 ± 52.1122.0 ± 45.60.31 (1.00, 1.01)0.633Total cholesterol levels [mmol/L] (mean ± SD)4.6 ± 1.24.6 ± 1.24.5 ± 1.20.20.89 (0.75, 1.05)0.158Total LDL levels [mmol/L] (mean ± SD)2.6 ± 1.12.7 ± 1.02.6 ± 1.10.30.91 (0.75, 1.10)0.323Total HDL levels [mmol/L] (mean ± SD)1.3 ± 0.41.3 ± 0.41.3 ± 0.40.60.79 (0.45, 1.37)0.41Total triglycerides levels [mmol/L] (mean ± SD)1.4 ± 0.91.5 ± 1.21.4 ± 0.60.80.86 (0.66, 1.07)0.21Cognitive impairment based on MoCA test at baseline and after 90 days (n, %)Consistently normal cognition: No cognitive impairment on baseline (MoCA: 23–30) and no cognitive impairment three months after stroke (MoCA: 23–30)150 (40.2%)84 (43.3%)66 (36.9%)0.3--Deterioration of cognitive performance: No cognitive impairment on baseline (MoCA: 23–30) and cognitive impairment three months after stroke (MoCA: 0–22)37 (9.9%)21 (10.8%)16 (8.9%)0.97 (0.46, 2.00)0.934Consistent cognitive decline: Cognitive impairment on baseline (MoCA: 0–22) and cognitive impairment three months after stroke (MoCA: 0–22)131 (35.1%)59 (30.4%)72 (40.2%)1.55 (0.97, 2.50)0.067Improvement of cognitive performance: Cognitive impairment on baseline (MoCA: 0–22) and no cognitive impairment three months after stroke (MoCA: 23–30)55 (14.7%)30 (15.5%)25 (14.0%)1.06 (0.57, 1.97)0.853Anxiety based on HADS- A - anxiety subscale at baseline and after 90. Days (n, %)Consistently no anxiety: No anxiety at baseline (HADS-A: 0–7); no anxiety after 3 months (HADS-A: 0–7)169 (45.4%)103 (54.2%)66 (36.3%)< 0.001 *--Deterioration in anxiety: no anxiety at baseline (HADS-A: 0–7); anxiety after 3 months (HADS-A: >7)74 (19.9%)26 (13.7%)48 (26.4%)2.88 (1.64, 5.14)< 0.001 *Consistent anxiety: anxiety at baseline (HADS-A: >7); anxiety after 3 months (HADS-A: >7)65 (17.5%)24 (12.6%)41 (22.5%)2.67 (1.49, 4.87)0.001 *Improvement in anxiety: anxiety at baseline (HADS-A: >7); no anxiety after 3 months (HADS-A: 0–7)64 (17.2%)37 (19.5%)27 (14.8%)1.14 (0.63, 2.04)0.663Depression based on HADS- D - depression subscale (at baseline and after 90 days (n, %)Consistently no depression: No depression at baseline (HADS-D: 0–7); no depression after 3 months (HADS-D: 0–7)218 (58.6%)125 (65.4%)93 (51.4%)< 0.001 *--Deterioration in depression: no depression at baseline (HADS-D: 0–7); depression after 3 months (HADS-D:>7)84 (22.6%)30 (15.7%)54 (29.8%)2.42 (1.45, 4.11)< 0.001 *Consistent depression: depression at baseline (HADS-D:>7); depression after 3 months (HADS-D:>7)41 (11.0%)16 (8.4%)25 (13.8%)2.10 (1.07, 4.23)0.033 *Improvement in depression: depression at baseline (HADS-D:>7); no depression after 3 months (HADS-D: 0–7)29 (7.8%)20 (10.5%)9 (5.0%)0.6 (0.25, 1.35)0.236 mRS score at hospital discharge 0–2 (n, %)338 (86.2%)181 (89.2%)157 (83.1%)0.08-- 3–5 (n, %)54 (13.8%)22 (10.8%)32 (16.9%)1.68 (0.94, 3.04)0.0821n (%)2Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test3Univariate logistic regression*statistically significant result Baseline characteristics of the studied population, comparison between two outcome groups (odds ratios with 95% confidence intervals) of univariate logistic regression models for the probability of group I (steady-state or improvement in OHRQoL as measured with the OHIP-14) vs. group II (deterioration in OHRQoL in the OHIP-14) three months after stroke 1n (%) 2Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test 3Univariate logistic regression *statistically significant result The initial analysis, utilizing univariate regression testing, identified that only deterioration in anxiety (OR = 2.88, 95%CI: 1.64–5.14, p < 0.001), consistent anxiety (OR = 2.67, 95%CI: 1.49–4.87, p = 0.001), deterioration in depression (OR = 2.42, 95%CI: 1.45–4.11, p < 0.001), consistent depression (OR = 2.10, 95%CI: 1.07–4.32, p = 0.033), all measured at the time of an acute stroke and 3 months later, and, additionally, higher platelet count (OR = 1.00, 95%CI: 1.00–1.01, p = 0.019) were associated with a decline in OHRQoL as assessed with the OHIP-14 questionnaire (see Table 1). Logistic regression analysis indicated that deterioration of anxiety (OR = 2.20, 95%CI: 1.20–4.09, p = 0.011), consistent anxiety (OR = 2.16, 95%CI: 1.15–4.11, p = 0.018), and higher platelet count (OR = 1.00, 95%CI: 1.00–1.01, p = 0.05) were independent risk factors for worsening of OHRQoL between the acute stroke period and 3 months afterwards. Deterioration of depression (OR = 1.72, 95%CI: 0.97–3.08, p = 0.065) and consistent depression (OR = 1.87, 95%CI: 0.91–3.93, p = 0.093) did not enter the multivariable logistic regression model looking for independent risk factors for worsening of OHRQoL (see Table 2). Table 2Multivariable logistic regression – model chosen in stepwise selection with backward elimination algorithm with the significance level at 0.05 – explaining deterioration in OHRQoL as measured with the OHIP-14CharacteristicsOR195% CI1p-valueHADS; A - anxiety subscale No anxiety at baseline; no anxiety after 90 days (reference category)—— Deterioration: no anxiety at baseline; anxiety after 90 days2.201.20, 4.090.011 * Permanent Anxiety: anxiety at baseline; anxiety after 90 days2.161.15, 4.110.018 * Improvement: anxiety at baseline; no anxiety after 90 days1.090.59, 1.980.778HADS; D - depression subscale No depression at baseline; no depression after 90 days (reference category)—— Deterioration: no depression at baseline; depression after 90 days1.720.97, 3.080.065 Permanent depression: depression at baseline; depression after 90 days1.870.91, 3.930.093 Improvement: depression at baseline; no depression after 90 days0.670.27, 1.520.353PLT count [x 103/uL]1.001.00, 1.010.050 *1OR Odds Ratio, CI Confidence Interval* statistically significant result Table 2Multivariable logistic regression – model chosen in stepwise selection with backward elimination algorithm with the significance level at 0.05 – explaining deterioration in OHRQoL as measured with the OHIP-14CharacteristicsOR195% CI1p-valueHADS; A - anxiety subscale No anxiety at baseline; no anxiety after 90 days (reference category)—— Deterioration: no anxiety at baseline; anxiety after 90 days2.201.20, 4.090.011 * Permanent Anxiety: anxiety at baseline; anxiety after 90 days2.161.15, 4.110.018 * Improvement: anxiety at baseline; no anxiety after 90 days1.090.59, 1.980.778HADS; D - depression subscale No depression at baseline; no depression after 90 days (reference category)—— Deterioration: no depression at baseline; depression after 90 days1.720.97, 3.080.065 Permanent depression: depression at baseline; depression after 90 days1.870.91, 3.930.093 Improvement: depression at baseline; no depression after 90 days0.670.27, 1.520.353PLT count [x 103/uL]1.001.00, 1.010.050 *1OR Odds Ratio, CI Confidence Interval* statistically significant result Multivariable logistic regression – model chosen in stepwise selection with backward elimination algorithm with the significance level at 0.05 – explaining deterioration in OHRQoL as measured with the OHIP-14 1OR Odds Ratio, CI Confidence Interval * statistically significant result Discussion Post-stroke patients are at risk of experiencing a decline in their OHRQoL due to physical, cognitive, and mental issues associated with stroke. This phenomenon’s incidence has not been systematically studied in the context of stroke. In our current study, we demonstrated for the first time that over 48% of stroke survivors experienced a decline in their OHRQoL. So far, a limited number of studies assessed a change in OHRQoL among patients after stroke. In a clinical trial from outpatient post-stroke rehabilitation center in Hong Kong, OHRQoL as measured with the OHIP-14 questionnaire did not change during 3 months of observation in a subgroup of subjects receiving conventional oral hygiene, but significantly improved during this period in people participating in an advanced programme comprising powered instead of manual toothbrush and chlorhexidine mouthrinse [12]. In a previous study performed in the same institution, stroke patients aged ≥ 50 exhibited significant improvement in the OHIP-14 score as measured 3 weeks apart, probably due to early reinitiation of oral hygiene [11]. Finally, in another longitudinal study from Hong Kong, OHRQoL measured with two questionnaires other than OHIP-14, improved among stroke patients between the acute phase of disease and six months after discharge from hospital; however, concomitant participation of caregivers in this study might at least partially explain better oral health over time [37]. On the other hand, a recent study from Thailand showed that general health-related quality of life in stroke survivors improved significantly up to 3 months post-discharge but not later on; noteworthy, such an improvement was not shown in subjects with severe stroke or insufficient monthly income [38]. As revealed in a previous Tunisian study, predictors of decreased quality of life one year after stroke were: older age, higher level of education, higher NIHSS score at 48 h, as well as disability and depression at 1 month [39]. Therefore, our study combined with the results of the previous research suggested that psychological illnesses, such as depression and anxiety, might play a potential role in deterioration of quality of life, both related to oral and general health. Notably, a decline in OHRQoL in our cohort between the acute phase of stroke and 3 months after its onset was significant, with a median difference in OHIP-14 score being 6, that exceeded the minimal clinically important difference of 4.45 points, as previously established [40]. Thus, our results seem clinically relevant and underline the need for multidisciplinary approach to rehabilitation of patients after stroke [41]. Awareness of OHRQoL in treatment of stroke survivors increased in the last decade, with American Heart Association/American Stroke Association (AHA/ASA) guidelines from 2016, recommending oral hygiene protocols in order to decrease a risk of aspiration pneumonia [42]. Most recent UK National Institute for Health and Care Excellence guidelines from 2023 regarding stroke rehabilitation in adults were more detailed and encouraged to maintain oral hygiene by regular tooth brushing and using mouthwash if needed, with emphasis on providing support from caregivers or family members for those who might have difficulty in following an oral hygiene regimen [43]. As our study has also suggested that anxiety or its deterioration may be a risk factor for decrease in OHRQoL, screening for psychological conditions, including anxiety and depression, with subsequent appropriate treatment, is necessary and stays in line with the current AHA/ASA guidelines [44]. Previous studies evaluating OHRQoL in stroke patients have focused primarily on two issues: (1) comparing OHRQoL between stroke patients and non-stroke controls [4, 45, 46], and (2) identifying factors influencing OHRQoL in stroke patients; these factors include oral health status [47], oral hygiene [11], socio-demographic variables [48, 49], and medical and neurological complications associated with stroke [13]. Among few studies comparing OHRQoL between stroke patients and healthy controls, McMillan et al. found no difference in the median Geriatric Oral Health Assessment Index score [45]. Conversely, Schimmel et al. [4] reported that acute stroke patients exhibited poorer OHRQoL, as measured with the OHIP-14, compared to controls. A large, recent population-based survey, ‘The Taiwan Longitudinal Study on Ageing’, demonstrated that stroke patients, among whom there were nearly 20% more individuals free from depression in relation to our cohort, had poorer OHRQoL compared to others [46]. Several studies have revealed that oral health parameters and hygiene behaviors significantly impact OHRQoL in stroke victims. Huang et al. in a large study found that age, toothache, self-rated oral health status, time since the last dentist visit, and reasons for not visiting the dentist in the past year influenced OHRQoL in stroke patients; however, in comparison to our study, this group comprised 22% more men and smoking was more than twice as common [48]. A Korean study with stroke patients over the age of 50, who received home care, identified that reduced activity of daily living, lower tooth brushing frequency per day, worse subjective general health status, and poor subjective oral health status were associated with OHRQoL as assessed with OHIP-14 [47]. Additionally, a large Hungarian cross-sectional study noted that low socio-demographic and economic status, along with low educational attainment, adversely affected OHRQoL among stroke survivors; these subjects compared to the participants in our study were nearly 7 years younger, most of them completed either high school or college/university education and – notably – 21.7% of them suffered from hemorrhagic stroke [49]. Further studies from China [50] and Hong Kong [11] demonstrated that oral hygiene behaviors were correlated with OHRQoL. While analyzing the medical and neurological consequences of stroke that may affect OHRQoL, several studies have focused on examining the correlation between post-stroke disability and OHRQoL. A study by Da Silva et al. [51] found that upper limb paresis in stroke survivors – leading to reduced physical capacity for self-care – was associated with poorer OHRQoL, as measured with the OHIP-14. Similarly, a study by Hunter et al. [52] also found that disability resulting in difficulty with tooth cleaning correlated with worse OHRQoL, again measured with the OHIP-14, within one year post-stroke. Comparable findings were reported by Moldvai et al. [49], who observed that the combination of stroke risk factors and residual impairments was linked to poor oral health. In our study, no significant correlation was found between parameter reflecting neurological deficit in the acute phase of stroke, i.e. delta NIHSS, and prognosis at discharge evaluated with mRS score. This lack of correlation is likely because the patients in our analysis do not represent the general post-stroke population as most of the participants were able to communicate and were largely independent. As mentioned before, we identified, for the first time, that consistent anxiety and worsening anxiety in stroke patients appeared to be an independent risk factors for the decline in OHRQoL 3 months post-stroke. Consistent depression and its worsening after stroke were identified as risk factors for declining OHRQoL in univariate analysis. However, this significance did not persist in multivariable analysis. PSA and PSD represent the most prevalent emotional consequences following stroke, impacting up to one-third of survivors [53]. Furthermore, both PSD and PSA are linked to diminished quality of life, delayed physical recovery, worsened long-term functional outcomes, and an increased risk of morbidity and mortality [54]. There is an increasing number of studies demonstrating a link between anxiety, chronic oral disorders, and OHRQoL. Cataldo et al. [55] conducted a study involving patients with periodontitis and controls, which revealed a correlation between periodontitis, anxiety, and the OHIP-14 score. Similarly, Celik et al. [56] found that OHRQoL worsened with temporomandibular disorders and deteriorated further as severity of anxiety increased. Furthermore, Yang et al. [57] reported that patients experiencing various chronic oral mucosal diseases exhibited increased anxiety and depression in tandem with declining OHRQoL. Several pathophysiological mechanisms have been postulated in order to explain relationship between mental health disorders, such as anxiety, and oral health, including disruption of oral microbiome in oral-gut-brain axis, chronic inflammation, nutritional deficiencies, neurotransmitter dysregulation, and stress-mediated pathways [58]. It was also suggested that anxious patients might change their habits that in turn affected oral health, including worsened hygiene or eating habits as well as intensive smoking [55]. It should also be noted that people with anxiety might present with different course over time, with most of them achieving remission, but 1 out of 5 experiencing intermittent or chronic symptoms [59]. In case of post-stroke patients, the link between quality of life and anxiety might also be mediated by sleep duration as shown previously [60]. Therefore, the anxiety–OHRQoL interplay seems complex and once again argues for multidisciplinary approach to screening and treatment of ischemic stroke survivors. Among 37 standardized demographic, clinical, radiological, and biochemical parameters available in patients with acute stroke, including cognitive issues, we found that only a higher platelet count correlated with the deterioration of OHRQoL as measured with the OHIP-14. This finding aligns with previous reports indicating that a platelet count at the upper end of the normal range in acute stroke is associated with poorer outcomes [61]. The elevated platelet count observed in acute stroke may reflect the presence of periodontitis – an association not measured in our study [62] but known to correlate closely with poor OHRQoL. Thus, the result of our study related to platelet count should be perceived as hypothesis-generating rather than conclusive. Nevertheless, screening for oral health conditions, such as periodontitis, is important among stroke survivors as this condition has been found to increase the risk of recurrent vascular events [63] and – lately – cognitive impairment in this population [64]. Noteworthy, platelet count in subjects who deteriorated in OHRQoL in our study, remained within normal limits, therefore, besides higher normal values of platelets might be a marker of inflammatory process, this result should be interpreted with caution, especially in isolation, and might not be relevant clinically [65]. Strengths and limitations The current analysis has several strengths. It is a prospective study involving a clearly defined population and a large sample size. Participants’ OHRQoL was assessed twice. The study examined numerous readily available parameters in acute stroke, along with cognitive status and mood disorders – specifically depression and anxiety – evaluated twice for each patient. Notably, only patients without a history of mood disorders or cognitive decline before stroke were included. We utilized standardized questions for participants or their caregivers to determine if cognitive decline or mood disorders were present before stroke. Additionally, we reviewed available medical documentation to confirm this information. Based on the medical history, none of the study participants received antidepressants or anxiolytics during hospitalization or throughout the follow-up period. Our study has several limitations. First of all, we did not perform objective clinical oral health assessment among study participants and did not gather data regarding their oral hygiene behaviors. Therefore, due to this key study limitation, it was not possible to separate the role of psychological conditions, including anxiety and depression, from confounding factors, such as oral health behavior or status [66]. Second, participants were recruited from a single medical center, focusing on a specific group of stroke survivors – those who were able to communicate and were mostly independent. Consequently, our results cannot be generalized to the entire population of stroke victims. Third, we did not account for oral health parameters, oral hygiene parameters, and socioeconomic status, which previous studies have identified as significant factors influencing OHRQoL [11, 47, 49, 50]. Conclusions Our study reveals that over 48% of ischemic stroke patients experience a decline in their OHRQoL. Our findings highlight the necessity for careful monitoring for PSA both early after stroke and during follow-up, as it influences the risk of future deterioration in OHRQoL. It is important to note that PSA can be managed with psychological and pharmacological interventions, which may lead to improvements in OHRQoL. Further research involving larger sample size and performed in other ethnic communities is needed to confirm our study’s results in this area. Supplementary Information Supplementary Material 1. Supplementary Material 1.